Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
177Lu-PNT6555 by Eli Lilly and Co for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
177Lu-PNT6555 is under clinical development by Eli Lilly and Co and currently in Phase I for Esophageal Squamous Cell Carcinoma...
177Lu-PNT6555 by Eli Lilly and Co for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
177Lu-PNT6555 is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Adenocarcinoma of The...
177Lu-PNT6555 by Eli Lilly and Co for Metastatic Colorectal Cancer: Likelihood of Approval
177Lu-PNT6555 is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Colorectal Cancer. According...
177Lu-PNT6555 by Eli Lilly and Co for Soft Tissue Sarcoma: Likelihood of Approval
177Lu-PNT6555 is under clinical development by Eli Lilly and Co and currently in Phase I for Soft Tissue Sarcoma. According...
177Lu-PNT6555 by Eli Lilly and Co for Solid Tumor: Likelihood of Approval
177Lu-PNT6555 is under clinical development by Eli Lilly and Co and currently in Phase I for Solid Tumor. According to...
177Lu-PNT6555 by Eli Lilly and Co for Metastatic Melanoma: Likelihood of Approval
177Lu-PNT6555 is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Melanoma. According to...